Belrestotug
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer[1][2].
Product Specifications
CAS Number
2574438-65-4
Product Name Alternative
EOS-448; EOS884448; GSK4428859A
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/belrestotug.html
Purity
97
Solubility
H2O
Smiles
[Belrestotug]
Molecular Weight
(145.7 kDa)
References & Citations
[1]Cuende J, et al. a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME) [J]. medRxiv, 2025: 2025.07. 25.25332187. |[2]Cuende J, et al. Pharmacodynamic assessment of a-TIGIT mAb EOS-448 highlights multiple FcγR-mediated mode-of-actions in blood and tumor of patients with advanced solid tumors[J]. Cancer Res, 2022, 82 (12_Suppl) : LB189.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
